Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HXN6005 Injection in Healthy Volunteers and Patients With Moderate-to-Severe Atopic Dermatitis
CTR20263076Phase 2Active
- Sponsor
- Helixon
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of HXN6005 in atopic dermatitis (AD), sponsored by Helixon. Started Aug 2026; status: active.
02
Drugs
HXN6005
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20263076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263076.